On October 28, 2015, an Illinois man filed an Invokana lawsuit seeking to hold the manufacturer responsible for his injuries. Anthony R. Allen, from Granite City, in Madison County, IL, filed his lawsuit against Janssen Pharmaceuticals, Inc., Johnson & Johnson Co., and Mitsubishi Tanabe Pharma... Read More
A Stockton, California woman, Jennifer Anzo, blames the diabetes drug Invokana for the diabetic ketoacidosis (DKA) and resulting complications she experienced in late 2013. On October 26, 2015, she filed a lawsuit in the United States District Court for the Eastern District of California against... Read More
While medical advances have created exceptional opportunities for Type 2 diabetics to manage and control their condition, several emerging treatment options have proven problematic and/or risky with long-term use. Specifically, the revolutionary drug Invokana (canagliflozin) was developed in recent years to alter the metabolic processes... Read More
The FDA has refused to grant approval for AstraZeneca’s latest diabetes drug, which combines two of the company’s existing diabetes medications. The federal agency would require further data to give the drug its blessing, which would mean additional clinical trials or the completion of ongoing trials. The new... Read More
A class action lawsuit filed in Canada alleges that Invokana can cause kidney failure and other life-threatening injuries in those who take the diabetes drug. Invokana belongs to a new class of medications called sodium-glucose cotransporter- 2(SGLT2) inhibitors and was only recently added to Nova... Read More
On September 10, the U.S. Food and Drug Administration issued a safety communication that the label of diabetes drug Invokana (canagliflozin) had been revised to include updates on bone fracture risk and new information on decreased bone mineral density. Invokana is a prescription medicine used with... Read More
Federal health regulators have recently raised concerns about diabetic ketoacidosis, a possible side effect of Invokana and other SGLT2 inhibitors. Researchers suggest that ensuring doctors are very clearly informed of the risk may help identify most cases and avert severe harm. The medical journal Diabetes... Read More
